The PrOMISE Study: PegvisOMant and the Immune SystEm
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms PrOMISE Study
- 05 Jul 2023 Status changed from active, no longer recruiting to completed.
- 10 May 2023 Planned number of patients changed from 30 to 60.
- 10 May 2023 Planned End Date changed from 30 Mar 2023 to 1 Jun 2023.